Ask about this productRelated genes to: CYP2D6 antibody
- Gene:
- CYP2D6 NIH gene
- Name:
- cytochrome P450 family 2 subfamily D member 6
- Previous symbol:
- CYP2DL1, CYP2D7P2, CYP2D7BP, CYP2D8P2, CYP2D7AP
- Synonyms:
- CPD6, P450-DB1, CYP2D, P450C2D
- Chromosome:
- 22q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-04-07
- Date modifiied:
- 2019-04-23
Related products to: CYP2D6 antibody
Related articles to: CYP2D6 antibody
- Latin American populations remain underrepresented in genomic research. To help address this, we present an analysis of high-coverage whole-genome data from 1481 volunteers recruited as part of the oriGen Project. We identify over 47.2 million SNVs and 8.1 million short indels, including nearly 3 million non-singleton short variants absent from dbSNP and the Mexico City Prospective Study. Admixture analysis indicates that a Mexican training dataset is needed to more accurately estimate ancestry compositions by genetic similarity. Analysis of copy number variation associated with MX-AMR highlights several loci, including LCE1D and RHD. Interestingly, while 3.1% of participants carry homozygous deletions in the RHD gene, which determines the Rh blood group, this frequency dropped to 0.6% among individuals with high MX-AMR. Since the RHD deletion is rare in East Asians, and the Rh-negative phenotype is rare in Indigenous American populations, our results support the hypothesis that the Rh-negative blood group increased in frequency during the Spanish conquest rather than by genetic drift. We also find that 10% of volunteers are heterozygotes for the 22-42128945-C-T Loss of Function variant in CYP2D6, an enzyme involved in metabolizing painkillers, and tamoxifen. This work helps address the underrepresentation of Mexican populations in genomic research. - Source: PubMed
Publication date: 2026/09/05
Aguilar-Ordoñez IsraelGuzman-Cerezo EugenioTorres-Treviño DavidColin-Oviedo AlvaroOrtiz-Lopez RocioGonzalez-Castillo Elena-CristinaRubio-Infante NestorRamirez-Vega JoseChavez-Santoscoy Rocio-AlejandraRuiz-Matus CuitlahuacDe-La-Cruz MartinGarcia-Rivas GeradoCardona ServandoKuri-Morales PabloTorre-Amione GuillermoTreviño Víctor - Children with congenital and acquired heart disease frequently require complex and prolonged pharmacotherapy, often involving off-label cardiovascular medications with narrow therapeutic ranges. Consequently, variability in drug response and medication-related adverse events remains a significant clinical challenge in pediatric cardiology. Pharmacogenetics provides a framework to individualize drug selection and dosing by incorporating genetic variability alongside established clinical and developmental factors. This review outlines the current clinical utility and emerging role of pharmacogenetics in pediatric cardiology, emphasizing applications most relevant to day-to-day patient care. Established pharmacogenetic associations with direct implications for pediatric cardiac practice include gene-drug pairs involving tacrolimus (), warfarin (, rs12777823 within the , clopidogrel (, flecainide (, metoprolol (, and statins (), many of which are supported by guideline-based recommendations from the Clinical Pharmacogenetics Implementation Consortium. This review also highlights pharmacogenetic considerations for commonly prescribed non-cardiac medications that may influence cardiovascular outcomes in children with heart disease, identifies emerging areas for research, and emphasizes that as pharmacogenetic testing becomes increasingly accessible, its thoughtful integration into pediatric cardiology practice may improve therapeutic precision, enhance safety, and reduce preventable adverse drug events. - Source: PubMed
Publication date: 2026/09/21
Adenikinju Adenike TWagner Jonathan BWalton Mollie M - - Source: PubMed
Publication date: 2026/09/01
Staller KyleClukey JennaMadva Elizabeth NHealy Brian CLee MinyiGala Manish K - Amitriptyline, mirtazapine, and escitalopram are effective antidepressants for treating major depressive disorder (MDD). Our study aimed to use computational biology to understand the mechanisms for the similarities and differences in efficacies and side effects of these drugs. - Source: PubMed
Publication date: 2026/10/02
Zhuo ChuanjunZhang QiuyuSong HaitaoZou JiatongLi RanliMa XiaoyanChen XimingLi YachenYang LeiWang LinaLi ChaoTian Hongjun - The advent of pharmacogenomics-guided antihypertensive therapy represents a paradigm shift in hypertension management. This study aimed to investigate the prevalence of relevant genetic variants among hypertensive patients in Hunan Province, China, and evaluate the efficacy of genotype-directed vs. clinically guided therapy. - Source: PubMed
Publication date: 2026/09/18
Wu ShaLiu WenwuChen LongXu YonglongJin JingChen FangLi JunHu WuhuiWu JieCai YongjunHuang ZiChai XiaoliShi XiangjiangLuo YanlinZeng GaofengZeng HaiyanChen ZhiGuo FugangWang LeiWu MingxinQu ZhihaoWang YuPeng Daoquan